Register D — Investment Writeup | Research date: 2026-04-26
Register D — Investment Writeup | Research date: 2026-04-26
Background. BS Chemical Engineering, Auburn University. Began his career as an engineer at National Semiconductor, then joined Unitive Electronics in the late 1990s — a Chapel Hill, NC-based advanced packaging startup focused on flip-chip and wafer-level packaging. Amkor acquired Unitive Electronics in 2004; Engel came with the deal. He then spent 22 consecutive years rising through Amkor: Corporate VP of Flip Chip/Wafer Services Business Unit → EVP of Business Units → EVP and COO (February 2025) → President and CEO (January 1, 2026).
Track record. Engel is an operational executive, not a promotional one. His entire post-2004 career was inside Amkor, running the product and operations side. He oversaw the business unit structure through Amkor’s advanced packaging push and was named COO immediately before the Arizona groundbreaking — implying the board wanted the operations leader running the company during the construction cycle. No public failures, regulatory actions, or prior company bankruptcies identified.
How he got the role. Internal succession from COO; announced Q3 2025, effective Q1 2026. Orderly, planned, no governance crisis. Rutten stayed advisory through March 2026 and remained on the board. Clean transition.
Red flags. None identified. No SEC enforcement, no PACER results for personal litigation, no prior company failures.
Background. Belgian national. Joined Philips in 1984; spent years in European and Asian semiconductor operations. Became SVP of Business Unit Home at NXP Semiconductors (spun off from Philips in 2006). Founded and led Ledzworld (LED technology company, circa 2012-2014) — a small venture; no evidence of success or notable failure. Joined Amkor in 2014 as EVP of Advanced Products; became President and CEO in June 2020 (during COVID, replacing John Kim who stepped down).
Track record at Amkor. Under Rutten (2020–2025): - Revenue grew from ~$5B (2020) to $7.1B (2022 peak) then retreated; recovered to $6.7B (2025) - Advanced packaging mix rose from ~65% to 82.8% — the single most strategically important shift - Korea Songdo campus built out significantly; Vietnam opened 2024 - Arizona campus committed, $7B investment — arguably the defining strategic act of his tenure - Intel EMIB partnership negotiated and announced Dec 2025 (his final month as CEO)
Red flags. None identified. No SEC actions, no securities fraud allegations, no related-party self-dealing found. Rutten is Belgian and his consulting engagement through March 2026 has been disclosed cleanly in the proxy.
Background. Career semiconductor finance executive. Prior roles not fully disclosed in public sources; joined Amkor February 2022. No significant public profile outside Amkor; no verified prior CEO/CFO roles at named public companies identified in searches. Educational background not confirmed.
Track record. Led the company through the FY2022 peak, the 2023-2024 cyclical decline, the 2025 recovery, the $487.5M equity raise, and the $500M note refinancing — a complex financing period. No earnings restatements, no material weaknesses in ICFR noted. The $487.5M equity raise and note refinancing in 2025 were well-executed: equity priced at $48.75 (secondary offering in February 2026 priced at the same level); notes refinanced at a lower coupon than the prior issuance. These are signals of competent treasury management.
Red flags. None identified. The limited public profile for a company of this size ($19B market cap) is mildly notable but not unusual for CFOs who focus on execution over investor relations.
Background. Senior legal officer; tenured at Amkor for multiple years. No significant public profile beyond the company. Has exercised options and sold shares under a 10b5-1 plan (adopted August 1, 2025).
Red flags. None identified. The 10b5-1 plan is best practice — it removes discretionary timing from insider sales.
Background. Commercial leadership. Runs all customer-facing relationships. Not a named executive officer in the proxy; compensation not publicly detailed. Limited public profile.
Red flags. None identified.
| Name | Role | Shares (approx.) | % of Outstanding | Est. Value | How Acquired |
|---|---|---|---|---|---|
| Kim family group (all entities combined) | Founder / Controlling shareholder | ~122.7M shares | ~49.5% (as of Feb 10, 2026) | ~$5.8B (at $47) | Founding stake; maintained; GRAT distributions; internal family transfers |
| Susan Y. Kim | Board Chairman (family) | Included in family group above | ~49.5% group | — | Inherited / transferred from James J. Kim |
| John T. Kim | Director / 10% owner | Via 915 Investments, LP and personal accounts | Subset of family group | — | Family; also bought ~441K shares Aug 2025 at $21.85 ($9.6M) |
| Kevin K. Engel | President & CEO | Small (RSUs + options + prior grants; exact count not confirmed) | <0.1% | ~$3-5M est. | Company grants over 22 years |
| Giel Rutten | Former CEO / Director | Not quantified; likely sold on exercise + retention grants | <0.1% | Small | Grants |
| Megan Faust | CFO | Small; not detailed | <0.1% | Small | Grants |
| Mark Rogers | EVP, General Counsel | Small; has exercised options under 10b5-1 | <0.1% | Small | Options grants ($7.40 exercise price; sold at $59.43 in Nov 2025) |
Net insider buying vs. selling (last 12-18 months):
| Date | Name | Transaction | Shares | Price | Value | Type |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | John T. Kim (10% owner) | Open market BUY | 441,589 | $21.85 | $9.6M | Open market purchase |
| Aug 1, 2025 | Kim David D. (family member) | Open market BUY | 441,589 | $21.85 | $9.6M | Open market purchase |
| Aug 1, 2025 | Sujoda Investments LP | Open market BUY | 441,589 | $21.85 | $9.6M | Open market purchase |
| Feb 2025 | Sujoda Management LLC | Open market BUY | 869,565 | $21.85 | $18.9M | Open market purchase |
| Nov 17, 2025 | Director Morse (Robert Randolph) | Option exercise + sell | 20,000 | $7.40 → sold at mkt | — | Exercise + cashless sale |
| Nov 2025 | Mark Rogers | Option exercise + sell | 5,000 | $7.40 → sold $59.43 | ~$260K gain | 10b5-1 plan |
| Dec 12, 2025 | Kevin Engel (then COO) | Open market SELL | 11,000 | $46.21 | $508K | Grant-related selling |
| Feb 12, 2026 | Kim family (915 Investments, LP) | Secondary offering SELL | 10,000,000 | $48.75 | $487.5M | Block secondary sale |
| Feb 24, 2026 | Kevin Engel (CEO) | RSU vesting + SELL | 12,500 | $48.75 | $609K | Post-vest sell (tax cover + discretionary) |
Key analytical observations:
Kim family bought $47M+ at the stock’s lows (Aug 2025 at $21.85 and Feb 2025 at $21.85). These were open-market purchases at a price the family clearly viewed as an opportunity. At the time, the stock had pulled back ~12% in a week. This is the strongest possible alignment signal: the family was putting real cash into the stock at depressed prices.
Kim family then sold 10M shares in February 2026 at $48.75 — more than doubling their money in six months relative to the Feb/Aug purchases at $21.85. This is straightforward portfolio management and intergenerational wealth transfer, not a bearish signal on the business. A 180-day lock-up was imposed on remaining shares. The family still retains ~49.5% after the sale.
Management executives (Rogers, Engel, Morse) are selling option-exercise proceeds, not discretionary holdings. This is normal — executives exercise low-strike options ($7.40) and sell into the market at higher prices. Not a red flag. Rogers used a proper 10b5-1 plan.
No open-market discretionary buying by non-Kim management. This is the typical pattern at large established companies; the family has so much concentrated wealth that their behavior subsumes management. Non-family executives’ lack of market buying is neutral, not negative.
10b5-1 plans. Rogers has one (adopted Aug 1, 2025). Best practice. No evidence of spring-loading or unusual pre-announcement timing.
| Name | Holdings in AMKR ($, %) | Other Public Co. Holdings | Private / Shell Interests | Where Is the Majority? |
|---|---|---|---|---|
| James J. Kim (Chairman Emeritus) | ~$2-3B (subset of family 49.5%) | No significant other public holdings found | Grantor Retained Annuity Trusts (GRAT), 915 Investments LP, Sujoda entities | Overwhelmingly in AMKR |
| Susan Y. Kim (Board Chairman) | ~$2-3B (subset of family 49.5%) | No significant other public holdings found | 915 Investments LP, Sujoda entities, trust vehicles | Overwhelmingly in AMKR |
| John T. Kim (Director, 10% owner) | ~$1-2B (subset of family 49.5%) | No significant other public holdings found | 915 Investments LP (sole general partner) | Overwhelmingly in AMKR |
| Kevin Engel (CEO) | ~$3-5M estimate (grants over 22 yrs) | None identified | None identified | Salary + annual cash comp likely dominant; AMKR equity modest but meaningful relative to salary |
| Megan Faust (CFO) | ~$2-4M estimate | None identified | None identified | Diversified personal portfolio likely; AMKR grants are not dominant |
Key finding. The Kim family’s wealth is concentrated almost entirely in AMKR. There is no diversification into other public equities or separate business ventures that would dilute their incentive to maximize Amkor’s value. This is the gold standard of alignment for a controlling shareholder. Their willingness to buy at $21.85 in 2025 (nearly $50M total committed across multiple family members and entities) while running a company with $7B in capital commitments outstanding is a strong conviction signal.
The Kim family ownership structure is disclosed in 13D/G filings and is not a shell structure — it is a conventional family holding structure:
James J. Kim (Founder, Chairman Emeritus)
│
├── Direct personal holdings
├── Grantor Retained Annuity Trusts (GRATs)
│ └── Distributes shares on schedule to next generation
├── 915 Investments, LP (John T. Kim, sole general partner)
│ └── ~3-4% of AMKR shares
└── Sujoda Investments, LP (Sujoda Management, LLC as GP)
└── Kim David D. / family members involved
└── ~3-4% of AMKR shares
Total family group: ~49.5% of Amkor common stock
(as of Feb 10, 2026; 122.7M shares out of 247.3M outstanding)Assessment. This is a standard multi-generational family holding structure using GRATs (a common estate planning vehicle) and LP entities. The entities hold only Amkor shares — they are not vehicles for doing business with the company. The 13D filings are current and complete. No evidence of asset transfers between the company and family entities, no management fees, no IP licensing to family-controlled entities.
2026 proxy: “Since January 1, 2025, there have been no related party transactions that are required to be reported under SEC rules.”
This is the cleanest possible outcome. No consulting fees to family entities, no IP licensing to insiders, no lease arrangements with related parties, no management fees. The proxy cites this explicitly.
Amkor’s subsidiary structure is multinational and complex by necessity (manufacturing operations in Korea, Japan, Vietnam, Portugal, Philippines, Taiwan, US) but is fully disclosed in the 10-K. The operating subsidiaries are wholly owned; no minority JVs with undisclosed related parties were identified. The GRAT/LP holding structure at the family level is above-the-company and does not interact with Amkor’s operations.
ASCII structure — simplified:
Amkor Technology, Inc. (Delaware, NASDAQ: AMKR)
│
├── Amkor Technology Korea, Inc. (operating sub — Korea)
├── Amkor Technology Japan K.K. (operating sub — Japan)
├── Amkor Technology Portugal, Unipessoal Lda (operating sub — Portugal)
├── Amkor Technology Vietnam Co., Ltd. (operating sub — Vietnam)
├── Amkor Technology Philippines, Inc. (operating sub — Philippines)
├── Amkor Technology Taiwan, Ltd. (operating sub — Taiwan)
└── [Arizona entity — under construction, 2025+]No undercapitalized affiliates, no asset shuffling patterns, no complex IP holding structures. Clean.
SEC enforcement. No active or historical SEC enforcement actions against Amkor Technology or its executives identified. SEC.gov search shows no enforcement releases against Amkor. Clean.
Securities class action. One prior securities class action was dismissed by the federal court — noted in Amkor’s own IR press release (“Amkor Announces Dismissal of Securities Lawsuit by Federal Court”). The lawsuit related to stock option grants; it was dismissed. This is historical and resolved.
Patent litigation. Amkor is both plaintiff and defendant in IP matters — this is normal for a semiconductor company with 50+ years of packaging IP. Notable cases: Amkor Technology, Inc. v. Tessera, Inc. (2014), Amkor Technology, Inc. v. Synaptics, Inc. (2015). These are IP enforcement actions by Amkor as plaintiff, not against Amkor for misconduct. No adverse findings against management.
Mold compound litigation. Amkor announced a favorable verdict in its IR (“Amkor Reports Favorable Verdict in Mold Compound Litigation”) — a supplier-related case, not a management fraud matter.
Overall litigation verdict: Clean. No management fraud, no SEC enforcement, no pattern of related-party self-dealing.
| Component | Amount |
|---|---|
| Base salary | $1,000,000 |
| Annual bonus | $1,498,500 (149.85% of base; tied to operating income of $343.9M) |
| Equity awards (stock) | ~$11.7M (multi-year PSUs + RSUs) |
| Other (housing, transport — Singapore-based posting) | ~$2.7M |
| Total | ~$16.9M |
Source: 2026 DEF 14A via StockTitan
Rutten context. The housing and transport allowances (~$2.7M “other”) relate to his Singapore posting (NXP-era arrangement; Rutten is Belgian). This is a meaningful additional benefit but is disclosed and was pre-existing. At $16.9M total comp for a $6.7B revenue company, Rutten’s pay is in the reasonable range for a semiconductor CEO of this scale — not extravagant.
2025 compensation committee action: reduced target bonuses by 25%. The committee cut bonus targets (while still paying above-target on operating income achievement) — this reflects calibration, not manipulation. The explicit 25% reduction was disclosed.
| Component | Amount |
|---|---|
| Base salary | $900,000 |
| Target annual incentive | 125% of base = $1,125,000 |
| LTI equity (February 2026 grant) | $5,000,000 (RSUs + PSUs) |
| Special RSU grant | $1,000,000 (vesting Dec 2026 and Dec 2027) |
| Target total | ~$7M |
Engel’s compensation is approximately 59% below Rutten’s on a total basis. This is a significant reduction, likely intentional — Engel is an internal promotion without the Singapore-based international premium. The lower base ($900K vs. $1M) also reflects a clean slate for a new CEO. This is well-calibrated compensation for the role.
Annual bonus metric. Operating income is the primary metric. This is better than revenue or EPS as a metric because it captures cost discipline as well as revenue growth, and it is not subject to capital structure manipulation (unlike EPS). The 2025 threshold was $343.9M operating income; actual was approximately $343.9M per the proxy (effectively at or just above threshold). The $25% target reduction reflected the committee’s judgment that the full target was not appropriate given the macro environment — but the actual operating income achievement still drove above-target payouts in total.
PSU metric. Multi-year PSUs are tied to “basic EPS” over a one-year performance period AND relative total shareholder return (TSR). The dual metric (EPS + relative TSR) is better governance than either metric alone. EPS hurdles drive fundamental performance; relative TSR hurdles ensure management is judged against peers, not just internal targets.
Performance grant forensics — PSU hurdles:
From the Form 4 (February 18, 2026): - PSU 1 (granted Feb 2024): vested 1,777 shares on EPS goal for 2025 performance period - PSU 2 (granted Feb 2025): vested 5,594 shares on EPS goal for 2025 performance period
These are small in dollar terms relative to base comp ($1.50 EPS × 1,777 shares = $2,665). The PSU tranches at the COO level (Engel was COO until Jan 2026) were modest. The new CEO grant ($5M LTI) will be Engel’s primary equity incentive going forward.
Hurdle vs. company plan: - Company FY2026 guidance: revenue $1.6-1.7B in Q1 (implies ~$7.2B full year); EPS ~$1.50 - PSU metric is EPS-based with TSR overlay - If company hits its own forward guidance, management clears the EPS threshold - Alignment: Moderate. EPS is the right metric but the hurdle structure isn’t disclosed in sufficient detail to verify whether the bar is aspirational or easily achievable. The compensation committee’s 25% target reduction in 2025 suggests they are actively calibrating, not rubber-stamping.
SBC as % of revenue. ~$8-10M annually (~0.12-0.15% of $6.7B revenue). Extremely low. No SBC dilution concern.
Anti-hedging / anti-pledging. In place per the proxy. Clean governance practice.
Stock ownership guidelines. Disclosed as required for executives and directors. CEO must maintain minimum ownership level. No specifics disclosed publicly.
Unusual perks. Rutten’s Singapore housing and transport ($2.7M) is the only notable item. Disclosed. Engel is Arizona-based; no offshore allowances expected.
Golden parachute. Not quantified in available data. No change-of-control triggers identified as excessive from available proxy data.
| Deal | Year | Target | Rationale | Outcome |
|---|---|---|---|---|
| Unitive Electronics | 2004 | Advanced packaging (flip-chip, WLP specialist) | Add advanced packaging capability | Success — Unitive’s technology became foundational; Engel (current CEO) came with this deal |
| J-Devices Corporation | 2019 | Japanese OSAT | Expand Japan automotive presence | Strategic fit; contributed Japan operating entity |
| No material M&A since 2019 | 2019-present | — | Organic investment focus | Capital directed to capex, not acquisitions |
No evidence of M&A value destruction. The last two deals were complementary acquisitions that enhanced capability rather than financial engineering. The absence of M&A since 2019 reflects capital discipline during the capex build cycle.
No material buyback program identified in recent history. During the current $7B Arizona commitment, this is rational — the company has no excess cash to deploy on buybacks. In the 2022 peak revenue year ($7.1B, $766M net income), the company could have initiated a buyback but chose to invest in capacity. Given the cycle dynamics and the strategic importance of the Arizona commitment, this is defensible.
| Year | Avg P/E | TECC (1/P/E) | Buyback | Equity Raise | M&A | Action Grade |
|---|---|---|---|---|---|---|
| 2022 | ~10-12x (peak rev) | ~8-10% | None | None | None | Neutral (missed buyback window) |
| 2023 | ~15-18x (downturn) | ~6-7% | None | None | None | Neutral |
| 2024 | ~20-25x | ~4-5% | None | None | None | Neutral |
| 2025 | ~25-35x (AI premium) | ~3-4% | None | $487.5M raise | None | Rational — raised equity at high P/E for needed capex |
| 2026 | ~30-35x (April 2026) | ~3-4% | None | Kim family secondary (not company issuance) | None | Neutral |
Assessment. Amkor raised equity in 2025 when the stock was at a premium multiple (high price, low TECC). From a cost-of-capital perspective, this was cheap equity for the company — they issued at expensive stock to fund the Arizona campus. This is the correct action: raise expensive equity when you need capital and the market will give it to you at favorable pricing. They did not buy back stock when the stock was cheap (2022-2024 with higher FCF) — this is a mild miss, but the company has been consistently capex-constrained, making buybacks difficult to justify even at lower prices.
Capital Allocation Timing Grade: Neutral-to-Good. Equity raise was well-timed; absence of buybacks during cheaper periods is a minor missed opportunity but understandable given capital needs.
| Quarter | Metric | Guided | Actual | Beat/Miss | Notes |
|---|---|---|---|---|---|
| Q2 2025 | Revenue | ~$1.4B midpoint | $1.51B | Beat ~8% | Exceeded on all end markets |
| Q3 2025 | Revenue | N/A (not found) | $1.99B | Record revenue | Beat consensus significantly |
| Q4 2025 | Revenue | Not provided in search | $1.89B | Beat high end | EPS $0.69 vs. $0.44 consensus (+57%) |
| Q1 2025 | Revenue | Upper bound guided ~$1.3B | $1.32B | At upper end | Met, not beat |
| Q3 2024 | EPS | $0.50 consensus | $0.49 | Miss -2% | Small miss; automotive weakness |
| Q4 2024 | Revenue | ~$1.6B guided | $1.629B | Slight beat | — |
Guidance tendency: Conservative / slight sandbagger. Q4 2025’s 57% EPS beat is an outlier (driven by strong Q4 mix), but the general pattern shows Amkor guiding conservatively and beating to the high end or above. The Q1 2025 result of “meeting the upper end” is consistent with conservative guidance. Q3 2024 had a small EPS miss ($0.01), likely due to automotive weakness materializing faster than guided. No pattern of large misses.
Credibility rating: High. Management consistently guides to achievable levels and beats modestly. No pattern of over-promising.
| Date | Source | What They Said | Hedge Language? | What Happened | Follow-Through? |
|---|---|---|---|---|---|
| Q3 2025 earnings call | Press release | Announced CEO succession; Engel to take over Jan 1, 2026 | No | Transition executed exactly as announced | ✅ |
| 2025 mid-year | Various calls | Arizona construction underway; on track for mid-2027 completion | Yes (“expected”) | Groundbreaking Oct 2025; on track per Feb 2026 earnings | ✅ |
| 2024 earnings calls | Earnings | Automotive inventory correction expected to normalize in 2025 | Yes (“expected to improve”) | Recovery slower than guided; 2025 showed partial improvement | ⚠️ |
| Q4 2025 earnings (Feb 2026) | Guidance | Q1 2026 guided $1.6-1.7B; GM 12.5-13.5% | No material hedging | Q1 2026 results on April 27 — not yet reported | Pending |
| 2025 | Proxy | “No related party transactions required to be reported” | None | Proxy statement confirms clean | ✅ |
Weasel language: Automotive recovery timing guidance used appropriate hedging (“expected,” “anticipate improvement”) rather than firm commitment — this was accurate hedging, not misleading language. No instances of “no current plans” followed by immediate reversals found.
Overall follow-through rate: ~4/5 = 80% on tracked statements. Guidance tendency: Conservative (slight sandbagger) Weasel language frequency: Low
Board composition: - 11 directors total; 9 classified as independent under Nasdaq standards - Chairman: Susan Y. Kim (non-independent; family) - Lead Independent Director: Gil C. Tily - Non-independent (non-family): Giel Rutten (former CEO; on board post-retirement) - 9 independent directors including John Liu (added December 2024)
Committee structure: - Audit Committee: independent directors; chaired independently; annual review of financial risk including cybersecurity - Compensation Committee: retained Compensia, Inc. as independent consultant; assessed no conflicts; administered say-on-pay in 2025 - Nominating/Governance: led by independent directors - Finance Committee: noted in proxy; likely oversees capital allocation decisions including Arizona
Board independence assessment. 9 of 11 independent is a good ratio. The Lead Independent Director role (Tily) provides a practical counterbalance to the family Chairman (Susan Kim). The Compensation Committee’s independent consultant (Compensia) and explicit conflict-of-interest assessment are best-practice governance.
Audit committee. Required to have at least one “audit committee financial expert” under SEC rules; Amkor is a large accelerated filer so this is mandatory and presumably compliant. The proxy references financial risk and cybersecurity oversight. No material weaknesses in ICFR noted in recent 10-K.
Related-party transactions. Per the proxy: none required to be reported in 2025. Clean.
Anti-takeover provisions. No formal poison pill or staggered board identified. The Kim family’s ~49.5% economic stake is itself the practical anti-takeover provision — no external acquirer can complete a transaction without family consent.
Shareholder proposals. Say-on-pay is an annual advisory vote. The 2025 proxy references the compensation committee’s 25% bonus reduction — this may be partly a response to shareholder feedback on pay-for-performance alignment. No contentious shareholder proposals identified.
M&A signal scan. No poison pill changes, no special meeting threshold amendments, no investment banker engagement for strategic alternatives. The only M&A-adjacent signal is the Kim family’s secondary offering in February 2026 — but at 10M shares out of 122M+ held, this is trivial (8%) and was paired with a 180-day lock-up. Not an exit signal.
| Dimension | Rating | Key Finding |
|---|---|---|
| Skin in the Game | Green | Kim family committed ~$50M in open-market purchases at $21.85 in 2025; net family ownership ~49.5%; wealth is overwhelmingly in AMKR |
| Holdings Concentration | Green | Kim family has no significant diversification; all-in on Amkor; strongest possible alignment |
| Shell / Cross-Holdings | Green | Clean; no related-party transactions in 2025; family holding entities (GRATs, 915 Investments, Sujoda) hold only AMKR shares and do not transact with the company |
| Capital Allocation | Yellow | Organic / capex-focused; no buyback track record; Arizona commitment is right strategy but untested at this scale; equity raise well-timed |
| Compensation Alignment | Green | Low SBC (0.12% of revenue); income-linked incentives (operating income + EPS + relative TSR); CEO comp reasonable; 25% bonus reduction shows active calibration |
| Credibility / Follow-Through | Green | Conservative guidance tendency; ~80% follow-through on tracked statements; clean hedging language; no misleading commitments |
| Governance Quality | Yellow | 9/11 independent board is good; Kim family Chairman with Lead Independent Director is appropriate balance; effective anti-takeover is family concentration (not an artificial device) |
| Litigation / Enforcement | Green | No SEC enforcement; one prior securities lawsuit dismissed; current and historical patent disputes are normal for OSAT; no personal litigation against executives |
| Overall Management Grade | B+ (Green-Yellow) | Exceptionally aligned founder-family structure; competent professional management; mild yellow on unproven large-scale capex execution and limited buyback discipline |
Green flags: - Kim family committed ~$50M in open-market AMKR purchases at depressed prices in 2025 — the most credible possible statement of conviction - Family wealth is entirely concentrated in AMKR; no diversification into other ventures that would dilute their focus - Proxy: zero related-party transactions in 2025 — the cleanest governance finding possible - SBC is negligible (0.12% of revenue); dilution risk is minimal - CEO transition was planned, orderly, and executed from within (22-year Amkor veteran) - Annual incentives tied to operating income; PSUs use EPS + relative TSR dual metric - Mark Rogers’ 10b5-1 plan adopted months before exercising — best practice, no spring-loading risk - Conservative guidance tendency; management consistently meets or beats its own guidance - No SEC enforcement, no securities fraud history, no material weaknesses in ICFR
Yellow flags: - Kim family sold 10M shares ($487.5M) in a secondary offering in February 2026 at $48.75. Put in context (family retains ~49.5% after sale; the shares were from 915 Investments LP), this is estate/portfolio management, not an exit. The 180-day lock-up is reassuring. However, the sell immediately following the Q4 2025 earnings beat (and just after the company raised equity from public investors) is worth noting — it puts some shares into the float at $48.75 when the company was guiding near-term gross margin compression. Yellow, not red. - Giel Rutten’s $2.7M annual housing/transport allowance: disclosed, but adds $2.7M to CEO “other” compensation in a way that would raise eyebrows at a leaner company. - No buyback track record: the company has never returned significant capital via buybacks, even in peak-revenue years. This is defensible given the capital intensity, but the absence of any buyback history means we have no data point on whether management understands the equity cost of capital. - CFO Megan Faust has limited public profile for a $19B company CFO. The work has been done competently, but the public profile opacity is mildly unusual.
Red flags: - None identified.
The Kim family’s concentrated ownership and demonstrated willingness to buy shares at market lows is the most important management finding: this is not a company where founders cashed out and management collects options. The ~$50M in open-market purchases at $21.85 in 2025 — while the company was simultaneously committing $7B to Arizona — represents the highest-conviction possible alignment signal. The professional management team (Engel, Faust, Rogers) is competent and credible, with a clean governance record, modest compensation, conservative guidance habits, and no red flags in SEC filings or litigation history. The family secondary sale in February 2026 is a yellow flag worth watching but does not change the fundamental ownership picture: 49.5% family ownership, 180-day lock-up, and a founding family with no diversification elsewhere. The capital allocation question mark (unproven at $7B scale, no buyback track record) is the only meaningful uncertainty. For a company of Amkor’s governance profile, I would trust this management team with capital.
Research date: 2026-04-26. Data sourced from SEC filings, proxy, Form 4s, and public databases.